300122.SHE Chongqing Zhifei Bio Products
- Market cap
- CNY 34.7B
- P/E
- -
- P/B
- 2.13x
- ROE
- -6.0%
- Dividend yield
- 0.99%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300122.SHE undervalued?
Graham numberThe Graham number of Chongqing Zhifei Bio Products cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chongqing Zhifei Bio Products fundamental analysis
No fundamental analysis for Chongqing Zhifei Bio Products yet.
Chongqing Zhifei Bio Products stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injectio…
Full company profileChongqing Zhifei Bio Products financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chongqing Zhifei Bio Products annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 446M | 1.34B | 5.23B | 10.6B | 15.2B | 30.7B | 38.3B | 52.9B | 26.1B | 8.96B | 8.72B |
| Gross Profit | 386M | 1.02B | 2.85B | 4.43B | 5.87B | 14.9B | 12.7B | 13.9B | 7.10B | 703M | 2.14B |
| Operating Income | 29.0M | 512M | 1.71B | 2.81B | 3.90B | 12.0B | 8.76B | 9.37B | 2.26B | -3.02B | -739M |
| EBITDA | 65.3M | 554M | 1.80B | 2.95B | 4.13B | 12.3B | 9.00B | 9.52B | 2.71B | -16.6B | -844M |
| Net Income | 32.5M | 432M | 1.45B | 2.37B | 3.30B | 10.2B | 7.54B | 8.07B | 2.02B | -14.7B | -911M |
| EPS | 0.02 | 0.27 | 0.91 | 1.48 | 2.06 | 6.38 | 3.14 | 3.36 | 0.84 | -6.15 | -0.38 |
| Balance Sheet | |||||||||||
| Total Assets | 2.71B | 4.11B | 6.81B | 10.9B | 15.2B | 30.0B | 38.0B | 50.2B | 49.9B | 31.7B | 27.1B |
| Total Liabilities | 188M | 1.17B | 2.63B | 5.20B | 6.97B | 12.4B | 13.8B | 18.7B | 19.1B | 15.6B | 11.7B |
| Shareholders' Equity | 2.52B | 2.94B | 4.18B | 5.75B | 8.25B | 17.7B | 24.2B | 31.5B | 30.8B | 15.8B | 15.2B |
| Cash & Short-term Investments | 658M | 874M | 769M | 1.20B | 1.44B | 4.31B | 2.62B | 6.34B | 2.70B | 2.63B | 2.32B |
| Total Debt | 1.51M | 260M | 621M | 2.38B | 2.88B | 818M | 2.02B | 2.99B | 12.3B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 90.0M | 204M | 586M | 1.37B | 3.50B | 8.51B | 1.99B | 9.00B | -4.41B | 5.17B | - |
| Capital Expenditure | 308M | 231M | 480M | 573M | 827M | 1.93B | 1.45B | 1.13B | 930M | 619M | 392M |
| Free Cash Flow | -218M | -27.2M | 106M | 794M | 2.67B | 6.58B | 536M | 7.86B | -5.34B | 4.55B | 4.83B |
| Ratios | |||||||||||
| ROE | 1.3% | 14.7% | 34.7% | 41.2% | 40.0% | 57.8% | 31.1% | 25.6% | 6.5% | -93.0% | -6.0% |
| ROA | 1.2% | 10.5% | 21.3% | 21.6% | 21.7% | 34.0% | 19.8% | 16.1% | 4.0% | -46.4% | -3.4% |
| Net Profit Margin | 7.3% | 32.2% | 27.8% | 22.4% | 21.7% | 33.3% | 19.7% | 15.2% | 7.7% | -164.3% | -10.4% |
| Debt to Equity | 0.00x | 0.09x | 0.15x | 0.41x | 0.35x | 0.05x | 0.08x | 0.09x | 0.40x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chongqing Zhifei Bio Products dividends
- Dividend yield
- 0.99%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 25, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 345M | 0.14 | - |
| 2024 | CNY 2.53B | 1.06 | 125.2% |
| 2023 | CNY 889M | 0.37 | 11.0% |
| 2022 | CNY 1.01B | 0.42 | 13.5% |
| 2021 | CNY 862M | 0.54 | 8.4% |
| 2020 | CNY 800M | 0.50 | 24.2% |
| 2019 | CNY 800M | 0.50 | 33.8% |
| 2018 | CNY 234M | 0.15 | 16.1% |
| 2017 | CNY 23.5M | 0.01 | 5.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.54:1 on Jun 16, 2023.
Who owns Chongqing Zhifei Bio Products
- Insiders 58.64%
- Institutions 7.90%
- Public & others 33.46%
- Shares outstanding 2.39B
- Free float 990M
Chongqing Zhifei Bio Products company profile
- Company name
- Chongqing Zhifei Bio Products
- Ticker
- 300122.SHE
- ISIN
- CNE100000V20
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Sep 28, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,292
- Fiscal year end
- December
- Address
- Building T1, IFS, Chongqing, China, 400020
- Phone
- 86 23 8635 8685
- Website
- zhifeishengwu.com
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.
Chongqing Zhifei Bio Products management
10- Mr. Lingfeng JiangVice Chairman of the Board & President · born 1980
- Mr. Zhen Jing Li CPAVP, CFO & Director · born 1982
- Mr. Zhijun WangChief Engineer · born 1966
- Mr. Fei QinVP, Secretary of Board & Director · born 1986
- Ms. Yu ZhangVice president · born 1987
- Ms. Zhang JingVice President · born 1969
- Mr. Jie ShaoVice President · born 1987
- Ms. Hong FanVice President · born 1988
- Ms. Li XieVice President · born 1982
- Mr. Xi Sheng JiangVice President · born 1960